东南国防医药
東南國防醫藥
동남국방의약
JOURNAL OF SOUTHEAST CHINA NATIONAL DEFENCE MEDICAL SCIENCE
2014年
6期
597-599,618
,共4页
来那度胺%复发难治多发性骨髓瘤%地塞米松
來那度胺%複髮難治多髮性骨髓瘤%地塞米鬆
래나도알%복발난치다발성골수류%지새미송
lenalidomide%relapsed and refractory multiple myeloma%dexamethasone
目的：探讨来那度胺联合地塞米松治疗复发难治多发性骨髓瘤的疗效。方法10例复发难治多发性骨髓瘤患者，一线化疗耐受，予来那度胺联合地塞米松方案治疗。结果应用该方案后，患者疾病均得到控制，M蛋白与β2微球蛋白显著下降，无完全缓解，部分缓解率为40％；至2014年7月5例进展患者的无进展生存期为8个月（5～10个月）；其余5例病情均稳定。该方案相关毒性反应较轻，患者能够耐受。结论来那度胺联合地塞米松治疗复发难治多发性骨髓瘤患者，具有一定疗效，患者耐受性好。
目的：探討來那度胺聯閤地塞米鬆治療複髮難治多髮性骨髓瘤的療效。方法10例複髮難治多髮性骨髓瘤患者，一線化療耐受，予來那度胺聯閤地塞米鬆方案治療。結果應用該方案後，患者疾病均得到控製，M蛋白與β2微毬蛋白顯著下降，無完全緩解，部分緩解率為40％；至2014年7月5例進展患者的無進展生存期為8箇月（5～10箇月）；其餘5例病情均穩定。該方案相關毒性反應較輕，患者能夠耐受。結論來那度胺聯閤地塞米鬆治療複髮難治多髮性骨髓瘤患者，具有一定療效，患者耐受性好。
목적：탐토래나도알연합지새미송치료복발난치다발성골수류적료효。방법10례복발난치다발성골수류환자，일선화료내수，여래나도알연합지새미송방안치료。결과응용해방안후，환자질병균득도공제，M단백여β2미구단백현저하강，무완전완해，부분완해솔위40％；지2014년7월5례진전환자적무진전생존기위8개월（5～10개월）；기여5례병정균은정。해방안상관독성반응교경，환자능구내수。결론래나도알연합지새미송치료복발난치다발성골수류환자，구유일정료효，환자내수성호。
Objective This study was to determine the efficacy and safety of treatment of relapsed and refractory multiple my -eloma combining lenalidomide with dexamethasone .Methods 10 patients with relapsed and refractory multiple myeloma who failed for first line chemotherapy were treated with lenalidomide and dexamethasone based chemotherapy .Results After the treatment ,the levels of immunoglobulin and β2-microglobulin were reduced significantly .The disease control rate was 100%,the partial response rate was 40%.The disease progressed in 5 patients by July 2014,and the median duration of progression-free was 8 months ( range,5 -10 months).Treatment-related toxicities were tolerant .Conclusion Lenalidomide-dexamethasone appears effective and tolerable in trea-ting patients with relapsed and refractory multiple myeloma .
